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Myocardial Infarction
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Objectives The aim of the AIDA STEMI (Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction) cardiac magnetic
resonance (CMR) substudy was to investigate potential benefits of intracoronary versus intravenous abciximab
bolus administration on infarct size and reperfusion injury in ST-segment elevation myocardial infarction.
Background The AIDA STEMI trial randomized 2,065 patients to intracoronary or intravenous abciximab and found similar
rates of major adverse cardiac events at 90 days with significantly less congestive heart failure in the intracoro-
nary abciximab group. CMR can directly visualize myocardial damage and reperfusion injury, thereby providing
mechanistic and pathophysiological insights.
Methods We enrolled 795 patients in the AIDA STEMI CMR substudy. CMR was completed within 1 week after
ST-segment elevation myocardial infarction. Central core laboratory–masked analyses for quantified ventricular
function, volumes, infarct size, microvascular obstruction, hemorrhage, and myocardial salvage were performed.
Results The area at risk (p  0.97) and final infarct size (16% [interquartile range: 9% to 25%] versus 17% [interquartile
range: 8% to 25%], p  0.52) did not differ significantly between the intracoronary and the intravenous abcix-
imab groups. Consequently, the myocardial salvage index was similar (52 [interquartile range: 35 to 69] versus
50 [interquartile range: 29 to 69], p  0.25). There were also no differences in microvascular obstruction (p 
0.19), intramyocardial hemorrhage (p  0.19), or ejection fraction (p  0.95) between both treatment groups.
Patients in whom major adverse cardiac events occurred had significantly larger infarcts, less myocardial sal-
vage, and more pronounced ventricular dysfunction.
Conclusions This largest multicenter CMR study in ST-segment elevation myocardial infarction patients to date demonstrates
no benefit of intracoronary versus intravenous abciximab administration on myocardial damage and/or reperfu-
sion injury. Infarct size determined by CMR was significantly associated with major adverse cardiac events.
(Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction [AIDA STEMI]; NCT00712101) (J Am Coll Cardiol
2013;61:1447–54) © 2013 by the American College of Cardiology Foundation
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sistently shown that treatment
with an adjunctive glycoprotein IIb/
IIIa inhibitor improves coronary mi-
crocirculation and clinical outcome
in high-risk ST-segment elevation
myocardial infarction (STEMI) pa-
tients undergoing primary percuta-
neous coronary intervention (PCI)
(1,2). Intracoronary abciximab bolus
administration results in higher local
concentrations and increased levels
of platelet glycoprotein IIb/IIIa re-
ceptor occupancy compared with
standard intravenous application (3).
Several meta-analyses suggested a
reduction in mortality and target-
vessel revascularization with intracoronary abciximab (4–6).
owever, in the large, randomized AIDA STEMI (Abcix-
mab Intracoronary versus intravenously Drug Applica-
Abbreviations
and Acronyms
CMR  cardiac magnetic
resonance
IQR  interquartile range
LV  left ventricular
MACE  major adverse
cardiac event(s)
MO  microvascular
obstruction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
Figure 1 Assessment of Myocardial Salvage, Infarct Size, Intra
(A) T2-weighted cardiac magnetic resonance image showing high signal intens
area of myocardial edema indicating intramyocardial hemorrhage. (B) Compute
myocardium (blue contour). The yellow overlay indicates a signal intensity of
of intramyocardial hemorrhage. (C) Contrast-enhanced image showing high sig
(D) Computer-aided signal intensity analysis of the contrast-enhanced image: l
dium (blue contour), whereas the yellow contour indicates the area of microva
(C, D) shows no relevant myocardial salvage.tion in STEMI) multicenter trial, intracoronary abcix-
imab application did not result in a difference in major
adverse cardiac events (MACE) compared with the
standard intravenous route (7), but the rate of new
congestive heart failure was significantly lower and there
was an observed benefit in the female subgroup. There-
fore, further analyses are warranted to assess potential
benefits of intracoronary abciximab.
See page 1455
Cardiac magnetic resonance (CMR) is uniquely suited to
provide important mechanistic and pathophysiological in-
formation on infarct size, myocardial salvage, microvascular
obstruction (MO), and intramyocardial hemorrhage (8–10).
The aim of the predefined AIDA STEMI CMR multi-
center substudy was to investigate potential benefits of
intracoronary abciximab application on myocardial damage,
reperfusion injury, and left ventricular (LV) function.
ardial Hemorrhage, and Microvascular Obstruction
he inferolateral segments (area at risk) with a hypointense core within the
d signal intensity analysis of the T2-weighted image normalized to normal
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ensity reflecting increased contrast accumulation in necrotic myocardium.
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Study design. The design and results of the AIDA STEMI
study were previously published (7,11). Briefly, AIDA STEMI
as a randomized, open-label, multicenter trial. Patients
resenting with STEMI 12 h were randomly assigned in
1:1 ratio to intracoronary or intravenous abciximab bolus
0.25 mg/kg bodyweight) during PCI with a subsequent
2-h dose-adjusted intravenous infusion.
Patients were enrolled at 22 sites in Germany, with a final
nrolled trial population of 2,065 patients. The primary
ndpoint was a composite of all-cause mortality, recurrent
nfarction, or new congestive heart failure within 90 days of
andomization.
MR substudy design. Consecutive patients enrolled at 8
ites were included in the CMR substudy. The sites were
hosen based on proven expertise in performing CMR exam-
nations in STEMI patients. Per protocol, CMR was per-
ormed on days 1 to 10 after the index event for assessment of
yocardial salvage, infarct size, presence and extent of MO,
nd LV ejection fraction and volume. The detailed scan
rotocol on a clinical 1.5- or 3.0-T magnetic resonance scanner
as described previously (11). CMR images were sent on
torable media to the CMR core laboratory at the University of
eipzig Heart Center (Leipzig, Germany) for blinded
ssessment.
mage analysis. For all quantitative analyses, certified CMR
valuation software was used (cmr42, Circle Cardiovascular
maging Inc., Calgary, Alberta, Canada). Semiautomated
omputer-aided threshold detection was used to identify re-
ions of edema, hypointense cores, MO, and infarcted myo-
ardium, as previously described (8–10) (Fig. 1).
Infarct size, area at risk, hypointense cores, and MO
ere expressed as a percentage of LV volume. Salvaged
yocardium was quantified as the difference between the
olume of increased T2-signal (area at risk) and the volume
f delayed enhancement (infarct size), as previously de-
cribed (9) (Fig. 1). The CMR core laboratory has
xcellent reproducibility and low interobserver and in-
raobserver variability for infarct size and myocardial
alvage assessment (12).
tatistical analysis. The study was powered for infarct size
a relative reduction in infarct size of 25% was considered
linically relevant). Evaluating 388 patients randomized to
ntracoronary or intravenous abciximab provided 80% power
o demonstrate a relative 25% reduction in infarct size from
4% to 18% (with 21% SD).
Data for continuous variables are presented as the median
ith the interquartile range (IQR). Categorical variables are
resented as frequencies and percentages. Testing for treat-
ent differences was performed with Wilcoxon rank sum tests
or continuous variables and chi-square tests for categorical
ariables.
Predefined subgroup analyses were performed according
o the original study protocol (7,11). Hazard ratios with
5% confidence intervals were calculated for binary out-omes. Univariate and stepwise multivariate linear regres-
ion analyses were performed to identify predictors of infarct
ize and myocardial salvage. Multivariate regression was
erformed using only variables with a p value 0.05 in
nivariate regression analyses. For univariate analyses, all
ariables listed in Table 1 were investigated. A 2-tailed
value of 0.05 was considered statistically significant.
esults
atient characteristics. From July 2008 to April 2011, 795
atients were enrolled in the AIDA STEMI CMR sub-
tudy (Fig. 2). Baseline characteristics of the total substudy
opulation and by randomized treatment are presented in
able 1. Patients in the 2 groups had similar baseline
haracteristics except for hypertension and previous bypass
urgery. All other prescribed drugs and study procedures
ere similar for both groups (Table 1).
MR findings. The median time between the index event
nd CMR was 3 days (IQR: 2 to 4 days) for both groups
p  0.70). Most patients underwent CMR on a 1.5-T
canner (97%). The main findings from CMR analyses are
resented in Table 2. There were no significant differences
n the area at risk, infarct size, and consequently myocardial
alvage, as well as for the occurrence and extent of MO
p  0.19) and intramyocardial hemorrhage (p  0.19).
In subgroup analyses, no significant treatment effect on
nfarct size could be detected (Fig. 3).
Thrombolysis In Myocardial Infarction flow before
CI correlated significantly with infarct size (r  0.360,
 0.001) and the myocardial salvage index (r  0.314,
 0.001). Significant independent predictors of infarct size are
displayed in Table 3. Independent predictors of the myocardial
salvage index were systolic blood pressure (p 0.001), time from
symptom onset to hospital admission for PCI (p 0.001), Killip
class on admission (p  0.001), Thrombolysis In Myocardial
Infarction flow before PCI (p 0.001), and left anterior descend-
ing lesion (p  0.03).
Clinical outcome and relationship of CMR markers and
clinical outcome. At 12-month follow-up, there were 13
deaths (3.3%) in the intracoronary and 8 (2.0%) in the
intravenous abciximab groups (hazard ratio: 1.69; 95% confi-
dence interval: 0.69 to 4.11; p  0.25). There were also no
significant differences in the occurrence of nonfatal reinfarc-
tions (p  0.54) and congestive heart failure (p  0.11).
Consequently, MACE at 12-month follow-up were similar (in-
tracoronary 24 [6.2%] vs. intravenous 29 [7.3%] events; hazard
ratio: 0.84; 95% confidence interval: 0.48 to 1.46; p  0.53).
Patients in whom MACE occurred had significantly
larger infarcts, less myocardial salvage, and more pro-
nounced LV dysfunction (Table 4). Intramyocardial hem-
orrhage and MO as markers of severe reperfusion injury
were more frequent in patients with MACE without reach-
ing statistical significance.
1450 Eitel et al. JACC Vol. 61, No. 13, 2013
The AIDA STEMI CMR Substudy April 2, 2013:1447–54Patient CharacteristicsTable 1 Patient Characteristics
Variable
Total CMR Substudy (n  795),
Main Trial (n  2,065)
Intracoronary Abciximab (n  394),
Main Trial (n  1,032)
Intravenous Abciximab (n  401),
Main Trial (n  1,033) p Value
Age, yrs 62 (51–71) 63 (51–71) 61 (51–71) 0.23
Male 603/795 (76) 287/394 (73) 316/401 (79) 0.05
Cardiovascular risk factors
Current smoking 339/727 (47) 161/364 (44) 178/363 (49) 0.19
Hypertension 540/792 (68) 284/393 (72) 256/399 (64) 0.01
Hypercholesterolemia 304/787 (39) 147/391 (38) 157/396 (40) 0.56
Diabetes mellitus
Any 160/792 (20) 87/392 (22) 73/400 (18) 0.17
Insulin requiring 74/792 (9) 40/392 (10) 34/400 (9) 0.41
BMI, kg/m2 27.3 (24.9–30.3) 27.4 (24.9– 30.1) 27.3 (24.8– 30.5) 0.78
Previous infarction 48/794 (6) 23/393 (6) 25/401 (6) 0.82
Previous PCI 67/795 (8) 35/394 (9) 32/401 (8) 0.65
Previous CABG 11/795 (1) 2/394 (1) 9/401 (2) 0.04
Anterior infarction 363/758 (48) 180/382 (47) 183/376 (49) 0.67
Systolic blood pressure, mm Hg 130 (117–147) 130 (116–145) 130 (117–150) 0.74
Diastolic blood pressure, mm Hg 80 (70–88) 80 (70–86) 80 (70–90) 0.19
Heart rate, beats/min 76 (67–87) 76 (67–86) 76 (67–88) 0.16
Creatinine clearance, ml/min* 94 (73–118) 92 (72–120) 96 (74–117) 0.28
Time from symptom onset to PCI
hospital admission, min
180 (109–310) 164 (108–300) 190 (110–335) 0.30
Door-to-balloon time, min 30 (22–42) 30 (22–43) 29 (22–42) 0.31
Killip class on admission 0.37
1 699/795 (88) 341/394 (87) 358/401 (89)
2 59/795 (7) 35/394 (9) 24/401 (6)
3 20/795 (3) 11/394 (3) 9/401 (2)
4 17/795 (2) 7/394 (2) 10/401 (3)
No. of diseased vessels 0.08
1 422/795 (53) 211/394 (54) 211/401 (53)
2 225/795 (28) 121/394 (31) 104/401 (26)
3 148/795 (19) 62/394 (16) 86/401 (21)
Infarct-related artery 0.53
Left anterior descending 347/795 (44) 166/394 (42) 181/401 (45)
Left circumflex 97/795 (12) 51/394 (13) 46/401 (12)
Right coronary artery 344/795 (43) 175/394 (44) 169/401 (42)
Left main 5/795 (1) 2/394 (1) 3/401 (1)
Bypass graft 2/795 (1) 0/394 (0) 2/401 (1)
TIMI flow grade before PCI 0.11
0 445/795 (56) 225/394 (57) 220/401 (55)
I 104/795 (13) 41/394 (10) 63/401 (16)
II 129/795 (16) 71/394 (18) 58/401 (15)
III 117/795 (15) 57/394 (15) 60/401 (15)
Stent implanted 777/795 (98) 385/394 (98) 392/401 (98) 0.84
Thrombectomy 190/795 (24) 99/394 (25) 91/401 (23) 0.42
Drug-eluting stent 335/793 (42) 164/392 (42) 171/401 (43) 0.77
Bare metal stent 69/793 (59) 234/392 (60) 235/401 (59) 0.81
TIMI flow grade post-PCI 0.59
0 12/794 (2) 6/394 (2) 6/400 (2)
I 19/794 (2) 9/394 (2) 10/400 (3)
II 62/794 (8) 36/394 (9) 26/400 (7)
III 701/794 (88) 343/394 (87) 358/400 (90)
Intra-aortic balloon pump 35/795 (4) 17/394 (4) 18/401 (5) 0.91Continued on the next page
coronar
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The AIDA STEMI CMR substudy is the largest multicenter
CMR study to assess markers of myocardial damage and
reperfusion injury in reperfused STEMI patients. The princi-
pal finding is that in patients with STEMI undergoing primary
PCI, intracoronary compared with intravenous abciximab bo-
lus administration did not result in a difference in infarct size,
myocardial salvage, LV function, or extent of reperfusion
injury, confirming the lack of difference in MACE. Further-
more, infarct size was significantly associated with outcome.
ContinuedTable 1 Continued
Variable
Total CMR Substudy (n  795),
Main Trial (n  2,065)
In
Concomitant medications
Beta-blockers 759/793 (96)
ACE inhibitors/AT-1 antagonist 754/793 (95)
Aspirin 795/795 (100)
Clopidogrel 678/768 (88)
Prasugrel 179/608 (29)
Clopidogrel, prasugrel, or both 775/775 (100)
Clopidogrel or prasugrel preloading 458/793 (58)
Statins 752/793 (95)
Aldosterone antagonist 91/793 (12)
Completion of abciximab infusion 748/794 (94)
Values are median (interquartile range) or n/N (%). *Creatinine clearance was calculated by the C
ACE  angiotensin-converting enzyme; AT-1 angiotensin 1; BMI  body mass index; CABG 
intervention; TIMI  Thrombolysis In Myocardial Infarction.
Figure 2 Study Profile
CMR  cardiac magnetic resonance; LGE  late gadolinium enhancement; LV  lThe main mechanism through which intracoronary ab-
ciximab may improve myocardial perfusion and clinical
outcome is the higher drug concentration, resulting in
increased local platelet inhibition, displacement of platelet-
bound fibrin, and dissolution of thrombi (13,14). Previous
studies demonstrated the superiority of intracoronary over
intravenous abciximab injection with respect to various
surrogate endpoints of effective reperfusion (4–6,15,16),
and these benefits were associated with improved survival in
3 different meta-analyses (4–6). However, the recently
completed AIDA STEMI trial, powered for clinical out-
nary Abciximab (n  394),
ain Trial (n  1,032)
Intravenous Abciximab (n  401),
Main Trial (n  1,033) p Value
373/393 (95) 386/400 (97) 0.27
372/393 (95) 382/400 (96) 0.58
394/394 (100) 401/401 (100)
330/381 (87) 348/387 (90) 0.15
92/310 (30) 87/298 (2) 0.90
385/385 (100) 390/390 (100)
226/394 (57) 232/399 (58) 0.88
367/393 (93) 385/400 (96) 0.07
49/393 (13) 42/400 (1) 0.39
370/393 (94) 378/401 (94) 0.94
ft-Gault formula.
y artery bypass graft; CMR  cardiac magnetic resonance; PCI  primary percutaneous coronary
tricular; MO  microvascular obstruction.tracoro
M
ockcroeft ven
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The AIDA STEMI CMR Substudy April 2, 2013:1447–54comes, found nearly identical MACE rates, whereas fewer
patients in the intracoronary group had new congestive
heart failure (7). Subgroup analyses showed the consistency
of the results in all subgroups except for women. The
reduction in new congestive heart failure events might have
been a consequence of improved perfusion and reduction in
infarct size by intracoronary abciximab. The use of CMR in
Cardiovascular Magnetic Resonance ResultsTable 2 Cardiovascular Magnetic Resonance Results
Characteristic Total CMR Substudy
Area at risk (edema), % LV 35 (25–48)
Infarct size, % LV 17 (8–25)
Myocardial salvage, % LV 17 (9–27)
Myocardial salvage index 51 (33–69)
Late MO present 381/774 (49)
Late MO, % LV 0 (0–1.8)
Hypointense core present (hemorrhage) 243/699 (35)
Hypointense core, % LV 0 (0–1.4)
LV ejection fraction, % 51 (43–58)
LV end-diastolic volume, ml 146 (120–173)
Values are median (interquartile range) or n/N (%).
CMR  cardiac magnetic resonance; LV  left ventricular; MO  microvascular obstruction.
Figure 3 Forest Plot Subgroup Analyses for Infarct Size
CI  confidence interval; LV  left ventricular volume; MI  myocardial infarction; PCIthis substudy allowed us to obtain further mechanistic
insight into the potential benefits of intracoronary abcix-
imab on reperfusion. In accordance with the clinical find-
ings, CMR showed almost identical results in both groups.
Similarly, in female patients, there was no effect on infarct
size or myocardial salvage. Thus, no pathophysiological and
biological rationale is apparent for the lower incidence of
tracoronary Abciximab Intravenous Abciximab p Value
35 (25–47) 35 (26–48) 0.97
16 (9–25) 17 (8–25) 0.52
18 (10–26) 16 (8–27) 0.43
52 (35–69) 50 (29–69) 0.25
180/384 (47) 201/390 (52) 0.19
0 (0–1.4) 0.2 (0–1.9) 0.22
112/346 (32) 131/353 (37) 0.19
0 (0–1.0) 0 (0–1.5) 0.22
51 (43–58) 50 (43–58) 0.95
146 (118–175) 146 (121–170) 0.83
cutaneous coronary intervention; TIMI  Thrombolysis In Myocardial Infarction.In per
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April 2, 2013:1447–54 The AIDA STEMI CMR Substudycongestive heart failure or for women, as suggested by the
clinical results of the AIDA STEMI trial.
Compared with previous studies, AIDA STEMI in-
cluded younger patients undergoing faster reperfusion with
better antiplatelet activation control (4–6). The INFUSE-
AMI (Intracoronary Abciximab Infusion and Aspiration
Thrombectomy in Patients Undergoing Percutaneous Cor-
onary Intervention for Anterior ST-Segment Elevation
Myocardial Infarction) trial differed in several ways from the
AIDA STEMI trial and all other previous studies (15).
First, bolus intracoronary abciximab was compared with
placebo. Second, only early presenting patients (4 h) with
anterior STEMI were enrolled. Third, bivalirudin was used
for anticoagulation during PCI. Fourth, a dedicated local
drug delivery balloon was used, whereas in almost all
previous trials, intracoronary abciximab was infused proxi-
mally through the guide catheter. The use of a local drug
delivery balloon may result in higher intraclot abciximab
concentrations with prolonged drug residence time, en-
hanced platelet disaggregation, and thrombus resolution
(14). However, overall, the magnitude of the absolute
infarct size reduction with intracoronary abciximab in the
INFUSE-AMI trial was modest (mean reduction, 2.3% LV
volume) and was not accompanied by other markers of
reperfusion success, and long-term follow-up needs to
demonstrate whether this translates into improved clinical
outcomes. In contrast to INFUSE-AMI, our twice as large
AIDA STEMI CMR substudy did not find a significant
infarct size reduction even in the subgroup of patients with
early reperfused (4 h) anterior infarcts (intracoronary:
19.0% LV volume [IQR: 10.6% to 28.5%]; intravenous:
19.2% LV volume [IQR: 7.2% to 28.8%]; p  0.53).
Two updated meta-analyses including the AIDA
STEMI results found no benefit in clinical outcome with
intracoronary abciximab administration, including mortality
and reinfarction (17,18). However, a significant relationship
between the patient risk profile and mortality could be
observed. Thus, there are still open questions worth study-
ing such as the appropriate patient group (e.g., exclusively
Predictors of Infarct Size inMult variate Regression A alysisTable 3 Pr dictors of Infarct Size inMultivariate Regression Analysis
Dependent Variable Infarct Size (% LV)
Multivariate Analysis:
Final Model
Coefficients
p ValueB SE
Heart rate, beats/min (continuous) 0.10 0.03 0.001
Systolic blood pressure, mm Hg (continuous) 0.07 0.02 0.001
Killip class on admission, 1 (I) 2 (II) 3 (III, IV) 4.05 0.84 0.001
No. of diseased vessels, 1–3 2.36 0.59 0.001
Right coronary artery lesion, 0 (no) 1 (yes) 2.85 1.07 0.01
TIMI flow before PCI: 0–3 3.43 0.35 0.001
Symptom onset to PCI hospital admission,
min (continuous)
0.01 0.00 0.02
2The final model explained 28% of the observed variance (adjusted R ).
Abbreviations as in Table 1.high-risk patients with high thrombus burden and large
myocardium at risk), the means of intracoronary abciximab
administration (role of selective delivery systems), and
concomitant medication.
Our CMR substudy findings provide an important per-
spective on the use of CMR as an endpoint in reperfusion
studies in acute STEMI. The current study is the largest
multicenter, multivendor investigation to evaluate the prog-
nostic significance of myocardial damage and reperfusion
injury as determined by CMR (15,19–21). Our data dem-
onstrate that MACE occurrence in reperfused STEMI
patients is directly related to infarct size, which strengthens
its use as a strong surrogate endpoint for clinical trials
investigating the success of reperfusion strategies. Future
studies on improved myocardial reperfusion should there-
fore consider CMR to provide a thorough evaluation and
understanding of therapeutic effects, improve risk stratifica-
tion, and ultimately prognosis.
Study limitations. The present study was conducted at 8
different centers using different CMR vendors. However, all
centers carefully followed the same protocol, and all data
were centrally analyzed by an experienced core laboratory.
Second, a significant portion of patients had incomplete
CMR scans. Because the proportion was identical in both
groups, a potential selection bias is limited.
Conclusions
In this largest CMR multicenter study to date in STEMI
patients undergoing primary PCI, intracoronary compared
with intravenous abciximab application did not result in a
difference in myocardial damage, LV function, or reperfu-
sion injury. Nevertheless, infarct size was significantly asso-
ciated with MACE.
Reprint requests and correspondence: Dr. Ingo Eitel or Dr.
Holger Thiele, Heart Center, Department of Internal Medicine/
Cardiology, University of Leipzig, Strümpellstr. 39, 04289 Leipzig,
Germany. E-mail: ingoeitel@gmx.de or thielh@medizin.
Relationship of CMR Markersand Cli ical Outcome at 12 MonthsTable 4 Relationship of CMR Markersand Clinical Outcome at 12 Months
Characteristic MACE No MACE p Value
Infarct size, % LV 24 (18–31) [50] 16 (8–24) [78] 0.001
Myocardial salvage index 37 (23–55) [44] 52 (33–69) [644] 0.01
Late MO present 28/50 (56) 350/718 (49) 0.32
Late MO, % LV 0.6 (0–2.7) [50] 0 (0–1.6) [718] 0.09
Hypointense core present
(hemorrhage)
19/47 (40) 222/645 (34) 0.47
Hypointense core, % LV 0 (0–2.1) [47] 0 (0–1.3) [645] 0.36
LV ejection fraction, % 40 (33–47) [53] 51 (44–58) [736] 0.001
Values are median (interquartile range) [n] or n/N (%).
MACE  major adverse cardiac events; other abbreviations as in Table 2.uni-leipzig.de.
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